Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye800 imaging in esophageal cancer surgery
NCT04161560Phase 1Unknown
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of cetuximab-IRDye 800CW in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Tumor to Background Ratio and Relative Adverse Drug Reaction at 14 days. Status: unknown.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04161560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161560.